Trial
NCT06405061
Evaluation of Effectiveness and Safety of HAIC in Combination With Adebrelimab and Bevacizumab for Potentially Resectable Hepatocellular Carcinoma
Phase IISUSPENDEDOPERATIONALConfidence: HIGH
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Collaborators
—
Condition
Adebrelimab
Intervention
Adebrelimab
Why stopped
Mid-term data analysis for the project has been completed; enrollment is now suspended.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-29